Mogamulizumab-kpkc injection is used to treat mycosis fungoides and Sézary syndrome, two types of cutaneous T-cell lymphoma ([CTCL], a group of cancers of the immune system that first appear as skin rashes), in adults whose disease has not improved, has gotten worse, or has come back after taking other medications. Mogamulizumab-kpkc injection is in a class of medications called monoclonal antibodies. It works by activating the immune system to attack cancer cells.
Mogamulizumab-kpkc injection comes as a solution (liquid) to be injected intravenously (into a vein) over at least 60 minutes by a doctor or nurse in a hospital or medical office. It is usually given once a week for the first four doses, and then once every other week for as long as your treatment continues. The length of treatment depends on how well your body responds to the medication and the side effects that you experience.
You may experience a serious or life-threatening reaction while you receive a dose of mogamulizumab-kpkc injection. These reactions are more common with the first dose of mogamulizumab-kpkc injection but may occur at any time during treatment. Your doctor may tell you to take certain medications before receiving your dose to prevent these reactions. Your doctor will monitor you carefully while you are receiving the medication. If you experience any of the following symptoms during or after your infusion, tell your doctor immediately: chills, shaking, nausea, vomiting, flushing, itching, rash, fast heartbeat, shortness of breath, coughing, wheezing, dizziness, feeling like passing out, tiredness, headache, or fever. If you experience any of these symptoms, your doctor will slow down or stop your infusion and treat the symptoms of the reaction. If your reaction is severe, your healthcare provider may decide not to give you any more infusions of mogamulizumab-kpkc.
Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
Before receiving mogamulizumab-kpkc injection,
Unless your doctor tells you otherwise, continue your normal diet.
If you miss an appointment to receive a dose of mogamulizumab-kpkc injection, call your doctor as soon as possible.
Mogamulizumab-kpkc injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
Some side effects can be serious. If you experience any of these symptoms or those in the HOW section, call your doctor immediately or get emergency medical treatment:
Mogamulizumab-kpkc injection may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online ( Web Site ) or by phone (1-800-332-1088).
In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at Web Site. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.
Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your body's response to mogamulizumab-kpkc injection.
Ask your pharmacist any questions you have about mogamulizumab-kpkc injection.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
AHFS® Consumer Medication Information. © Copyright, The American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.
Selected Revisions: December 15, 2018.